Charles Raison

RAIsonance Launches the Air Quality Human Impact Program

Retrieved on: 
Tuesday, August 29, 2023
Sentinel, Atmosphere, Charles Raison, Respiratory system, Lead, Fire, Sulfur dioxide, Movement, Science, Organization, EPA, Carbon monoxide, Nitrogen dioxide, Particulates, FCV, IQAir, Health, Environment

GREENWOOD VILLAGE, Colo., Aug. 29, 2023 /PRNewswire/ -- RAIsonance today announced the release of its Air Quality Human Impact Program (AQHIP) for the US market.

Key Points: 
  • GREENWOOD VILLAGE, Colo., Aug. 29, 2023 /PRNewswire/ -- RAIsonance today announced the release of its Air Quality Human Impact Program (AQHIP) for the US market.
  • The completely new, specialized biometric monitoring system tracks and reports on the impact of poor air quality on the human respiratory system.
  • Access to the air quality data for those sensors is readily available from reputable organizations such as BreezeoMeter, IQAir, PurpleAir, and the EPA's AirNow.gov.
  • "Until now there has been no comprehensive, science-based way to quantify the real-time impact of poor air quality on our bodies, or to observe for how long those impacts last", said Kitty Kolding, CEO of RAIsonance.

RAIsonance Releases New Fall 2023 Workforce Risk Forecast

Retrieved on: 
Tuesday, August 22, 2023
Sentinel, Bureau of Labor Statistics, Workforce, Clouding of consciousness, Presenteeism, COPD, Asthma, LC, Health, SARS-CoV-2, Parent, Infection, COVID-19, Risk management, Charles Raison, COVID, Harvard Business Review, CDC, Incidence, RSV, Absenteeism, Brain, Mining, Korea Disease Control and Prevention Agency, Adenoviridae, Morale, Environment, Disease, Construction, Pharmaceutical industry, Vaccine, Omicron

GREENWOOD VILLAGE, Colo., Aug. 22, 2023 /PRNewswire/ -- RAIsonance today announced the release of its Fall 2023 Workforce Wellness Risk Forecast Report.

Key Points: 
  • GREENWOOD VILLAGE, Colo., Aug. 22, 2023 /PRNewswire/ -- RAIsonance today announced the release of its Fall 2023 Workforce Wellness Risk Forecast Report.
  • This specialized forecast delivers comprehensive insights into rising health risks likely to affect workforce health and productivity this fall, across industries and sectors.
  • The Fall 2023 report cites several specific trends that could create a very challenging environment for employers through the remainder of 2023.
  • "To support our enterprise clients, we watch these increasing workforce wellness threat indicators very closely," said Kris Hopkins, Chief Product Officer at RAIsonance.

RAIsonance, Inc. Announces BARDA Contract to Continue Development of the AudibleHealth Dx Diagnostic SaMD for COVID-19 and Influenza Through AI-Powered Cough Analysis

Retrieved on: 
Wednesday, April 12, 2023
United States Department of Health and Human Services, ASPR, Medical device, Biomedical Advanced Research and Development Authority, Office of Inspector General, U.S. Department of Health and Human Services, HHS, Human services, COVID-19, University, Administration for Strategic Preparedness and Response, Charles Raison, Drive, Global health, Organization, Administration, Development, Diagnosis, Entrepreneurship, FCV, Government, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, Food, Software

DENVER, April 12, 2023 /PRNewswire/ -- RAIsonance, Inc., the leader in artificial intelligence-powered analysis of FCV, announced today it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), a U.S. government agency.

Key Points: 
  • The contract consists of just over $749,000 allocated to the continued development of RAIsonance's AudibleHealth Dx Software as a Medical Device (SaMD).
  • The device is designed to analyze a user's Forced Cough Vocalization (FCV) in the diagnosis of illness, with the current focus on both COVID-19 and Influenza.
  • RAIsonance's SaMD is designed to use only software to diagnose disease, without any wet or biological samples of any kind.
  • The SaMD is scalable – able to process 20,000 tests per second – an ideal solution for large organizations, colleges and universities, and government agencies.

MyAdvocate, AI Cough Analysis Technology to Help Young People Quit Harmful Smoking and Vaping Habit

Retrieved on: 
Thursday, March 23, 2023
Smoking, Nicotine, Parent, Charles Raison, Android, Cough, Vacuum breaker, School, Student, Artificiality, Michael Soter, Artificial intelligence, FCV, Education, Safety, Herbal cigarette, Medical device, Tobacco, Apple

RONKONKOMA, N.Y., and DENVER, March 23, 2023 /PRNewswire-PRWeb/ -- Soter Technologies, the Long Island-based creators of the world's first vape detection and alert system for schools, has partnered with Denver-based RAIsonance Inc., a family of companies dedicated to Artificial Intelligence/Machine Learning (AI/ML)-based solutions for the safety, security, and healthcare diagnostics markets. The companies will work together to bring MyAdvocate, a Rapid Biometric Cough Signature Analysis Technology app, to schools and parents to support the reduction of youth vaping and smoking.

Key Points: 
  • The companies will work together to bring MyAdvocate, a Rapid Biometric Cough Signature Analysis Technology app, to schools and parents to support the reduction of youth vaping and smoking.
  • MyAdvocate for Vape Recovery and Smoking Recovery is a completely new, biometric tracking app that detects and measures the respiratory improvements users achieve while quitting smoking or vaping.
  • Using artificial intelligence, MyAdvocate technology compares Forced Cough Vocalization (FCV) signatures, which are intentional coughs, to the user's previously created baseline.
  • Soter's experience in the K-12 market, mobile application and backend monitoring technology have been paired with RAIsonance's AI cough analyzer technology.

RAIsonance Submits EUA Application to FDA for AudibleHealth Dx

Retrieved on: 
Tuesday, September 27, 2022
Clinical trial, Cough, University, Government, Health, EUA, Laboratory, Safety, Association of Public Health Laboratories, Infection, COVID-19, Machine learning, Policy, FDA, Food, Prevalence, Knowledge, Organization, Public, NPA, FCV, COVID, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intelligence, Denver Technological Center, CEO, PPA, Technology, CTO, SBIR, National Science Foundation, Public health, Patient portal, Diagnosis, Artificial intelligence, Science, CLIA, Board, RT, Ageing, Association, Charles Raison, Medical device, Pharmaceutical industry, Online shopping

GREENWOOD VILLAGE, Colo., Sept. 27, 2022 /PRNewswire/ -- RAIsonance, Inc., today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its AudibleHealth Dx Software as a Medical Device (SaMD).

Key Points: 
  • GREENWOOD VILLAGE, Colo., Sept. 27, 2022 /PRNewswire/ -- RAIsonance, Inc., today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its AudibleHealth Dx Software as a Medical Device (SaMD).
  • "I am beyond thrilled to have submitted our EUA Application for AudibleHealth Dx," said RAIsonance Founder and CEO, Kitty Kolding .
  • For the clinical validation study, the AudibleHealth Dx SaMD's ability to correctly diagnosis COVID-19 was compared to the BioFireRP2.1Panel (the first FDA de novo-authorized test for COVID-19).
  • Founded in March of 2020, AudibleHealth AI, Inc. is the SaMD division of RAIsonance, specializing in AI/ML diagnostic solutions and platforms.

RAIsonance Releases Preliminary Results from AudibleHealth Dx Validation Study

Retrieved on: 
Friday, August 26, 2022
National Science Foundation, COVID-19, CEO, Technology, Safety, Artificial intelligence, RT, Science, De novo, Organization, CLIA, Medical device, Charles Raison, Association, Patient, Association of Public Health Laboratories, University, EUA, Ageing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NPA, Board, Food, Intelligence, Infection, FDA, Denver Technological Center, Ecosystem, PPA, Efficiency, Machine learning, Laboratory, Patient portal, Food and Drug Administration, MD, Clinical trial, SBIR, CTO, Health, Government, Public, Cough, Public health, FCV, Policy, Diagnosis, Emergency Use Authorization, COVID-19 testing, Prevalence, Knowledge, Pharmaceutical industry, Vaccine, Online shopping

GREENWOOD VILLAGE, Colo., Aug. 26, 2022 /PRNewswire/ -- RAIsonance, Inc., a group of AI-powered technology solutions companies, today reported the preliminary results of its AudibleHealth Dx clinical validation study.

Key Points: 
  • GREENWOOD VILLAGE, Colo., Aug. 26, 2022 /PRNewswire/ -- RAIsonance, Inc., a group of AI-powered technology solutions companies, today reported the preliminary results of its AudibleHealth Dx clinical validation study.
  • In Q2 of 2022, RAIsonance commenced its Clinical Trial in Florida to validate the AudibleHealth Dx device's efficacy.
  • The study was a prospective, multi-site, non-inferiority trial that compared the AudibleHealth Dx COVID-19 test to a highly sensitive de novo-authorized RT-PCR COVID-19 test when using the AudibleHealth Dx SaMD to detect COVID-19 infections.
  • For the clinical validation study, the AudibleHealth Dx SaMD's ability to correctly diagnosis COVID-19 was compared to the BioFire RP2.1 Panel (the first FDA de novo-authorized test for COVID-19).

Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin

Retrieved on: 
Tuesday, December 15, 2020
Charles Nemeroff, Emory University, Healthcare in the United States, Pascal J. Goldschmidt, Charles Raison

Dr. Nemeroff is chair and professor with the Department of Psychiatry and Behavioral Sciences at the University of Texas at Austin Dell Medical School.

Key Points: 
  • Dr. Nemeroff is chair and professor with the Department of Psychiatry and Behavioral Sciences at the University of Texas at Austin Dell Medical School.
  • The addition of Dr. Nemeroff rounds out a diverse body of researchers and critical thinkers on our Scientific Advisory Board.
  • He received his medical degree and doctorate degrees in neurobiology from the University of North Carolina (UNC) School of Medicine.
  • After psychiatry residency training at UNC and Duke University, he held faculty positions at Duke University Medical Center and at Emory University School of Medicine before relocating to the University of Miami in 2009.